Sling Therapeutics closed a $123 million Series C funding round to advance its oral thyroid eye disease candidate, targeting a late-stage readout through Phase 3. The company is positioning the therapy as a potential first oral alternative to approved injectable treatments such as Amgen’s Tepezza. The funding highlights continued investor appetite for differentiated delivery and convenience in ophthalmic immunology, a category that has drawn heavy VC and pharma attention. Operationally, the Series C is aimed at sustaining trial execution through Phase 3 and toward commercialization if efficacy and tolerability expectations are met.